Development of Drug-Induced Interstitial Lung Disease After More Than 4-Years Treatment With Edoxaban: A Case Report.

Takata, Eriko; Kitahara, Kanayuki; Tanaka, Nao; Kusunoki, Yumiko; Ando, Mutsumi; Inoue, Daisuke; Shikama, Yusuke; Sunaga, Tomiko

Takata, Eriko; Kitahara, Kanayuki; Tanaka, Nao; Kusunoki, Yumiko; Ando, Mutsumi; Inoue, Daisuke; Shikama, Yusuke; Sunaga, Tomiko.

Takata E; Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Shinagawa-ku, Tokyo, Japan.
Kitahara K; Department of Pharmacy, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.
Tanaka N; Department of Pharmacy, Kameda General Hospital, Kamogawa, Chiba, Japan.
Kusunoki Y; Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Shinagawa-ku, Tokyo, Japan.
Ando M; Department of Pharmacy, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.
Inoue D; Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Shinagawa-ku, Tokyo, Japan.
Shikama Y; Department of Pharmacy, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.
Sunaga T; Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Shinagawa-ku, Tokyo, Japan.

Am J Ther ; 30(1): e77-e80, 2023.

Article in English | MEDLINE | ID: covidwho-2245605

Subject(s)

Anticoagulants; Lung Diseases, Interstitial; Humans; Pyridines/adverse effects; Thiazoles/adverse effects; Lung Diseases, Interstitial/chemically induced; Lung Diseases, Interstitial/diagnosis; Factor Xa Inhibitors/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lung Diseases, Interstitial / Anticoagulants Type of study: Case report / Diagnostic study Limits: Humans Language: English Journal: Am J Ther Journal subject: Therapeutics Year: 2023 Document Type: Article Affiliation country: MJT.0000000000001542

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google